SGLT2 抑制剂在虚弱中的功能和临床重要性：从肾脏到心脏。
Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart.
机构信息
Department of Medicine, Einstein-Sinai Diabetes Research Center, Einstein Institute for Aging Research, Fleischer Institute for Diabetes and Metabolism - FIDAM, Albert Einstein College of Medicine, New York, NY (G.S., F.V., S.W., A.d.D., A.L., S.S.J., U.K., P.M.).
Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Neuroimmunology and Inflammation, Albert Einstein College of Medicine, New York, NY (G.S., F.V., S.S.J., U.K.).
出版信息
Hypertension. 2023 Sep;80(9):1800-1809. doi: 10.1161/HYPERTENSIONAHA.123.20598. Epub 2023 Jul 5.
SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) act by increasing glycosuria, thereby reducing glycemia. These drugs are critical to reach and keep glycemic control, a crucial feature, especially in patients with comorbidities, like frail individuals. Several studies evaluated the effects of SGLT2-inhibitors in different settings beyond diabetes, revealing that they are actually pleiotropic drugs. We recently evidenced the favorable effects of SGLT2-inhibition on physical and cognitive impairment in frail older adults with diabetes and hypertension. In the present overview, we summarize the latest clinical and preclinical studies exploring the main effects of SGLT2-inhibitors on kidney and heart, emphasizing their potential beneficial actions in frailty.
SGLT2（钠-葡萄糖协同转运蛋白 2）可促进肾脏对葡萄糖和钠的重吸收。SGLT2 抑制剂（也称为格列净，包括卡格列净、达格列净、恩格列净和埃格列净）通过增加尿糖排泄来发挥作用，从而降低血糖。这些药物对于控制血糖至关重要，尤其是对于合并症患者（如体弱患者）。多项研究评估了 SGLT2 抑制剂在糖尿病以外的不同环境中的作用，结果表明它们实际上是多效药物。我们最近发现 SGLT2 抑制剂对糖尿病合并高血压的体弱老年人的身体和认知功能障碍有有益影响。在本综述中，我们总结了最新的临床和临床前研究，探讨了 SGLT2 抑制剂对肾脏和心脏的主要作用，强调了它们在体弱方面的潜在有益作用。
Zotero 插件